Literature DB >> 24622368

Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study [corrected].

Kanetee Busiah1, Séverine Drunat2, Laurence Vaivre-Douret3, Amélie Bonnefond4, Albane Simon5, Isabelle Flechtner6, Bénédicte Gérard2, Nathalie Pouvreau2, Caroline Elie7, Revital Nimri8, Liat De Vries8, Nadia Tubiana-Rufi9, Chantal Metz10, Anne-Marie Bertrand11, Sylvie Nivot-Adamiak12, Marc de Kerdanet12, Chantal Stuckens13, Farida Jennane14, Pierre-François Souchon15, Claire Le Tallec16, Christelle Désirée2, Sabrina Pereira2, Aurélie Dechaume4, Jean-Jacques Robert6, Moshe Phillip8, Raphaël Scharfmann17, Paul Czernichow6, Philippe Froguel18, Martine Vaxillaire4, Michel Polak19, Hélène Cavé20.   

Abstract

BACKGROUND: Neonatal diabetes mellitus is a rare genetic form of pancreatic β-cell dysfunction. We compared phenotypic features and clinical outcomes according to genetic subtypes in a cohort of patients diagnosed with neonatal diabetes mellitus before age 1 year, without β-cell autoimmunity and with normal pancreas morphology.
METHODS: We prospectively investigated patients from 20 countries referred to the French Neonatal Diabetes Mellitus Study Group from 1995 to 2010. Patients with hyperglycaemia requiring treatment with insulin before age 1 year were eligible, provided that they had normal pancreatic morphology as assessed by ultrasonography and negative tests for β-cell autoimmunity. We assessed changes in the 6q24 locus, KATP-channel subunit genes (ABCC8 and KCNJ11), and preproinsulin gene (INS) and investigated associations between genotype and phenotype, with special attention to extra-pancreatic abnormalities.
FINDINGS: We tested 174 index patients, of whom 47 (27%) had no detectable genetic defect. Of the remaining 127 index patients, 40 (31%) had 6q24 abnormalities, 43 (34%) had mutations in KCNJ11, 31 (24%) had mutations in ABCC8, and 13 (10%) had mutations in INS. We reported developmental delay with or without epilepsy in 13 index patients (18% of participants with mutations in genes encoding KATP channel subunits). In-depth neuropsychomotor investigations were done at median age 7 years (IQR 1-15) in 27 index patients with mutations in KATP channel subunit genes who did not have developmental delay or epilepsy. Developmental coordination disorder (particularly visual-spatial dyspraxia) or attention deficits were recorded in all index patients who had this testing. Compared with index patients who had mutations in KATP channel subunit genes, those with 6q24 abnormalities had specific features: developmental defects involving the heart, kidneys, or urinary tract (8/36 [22%] vs 2/71 [3%]; p=0·002), intrauterine growth restriction (34/37 [92%] vs 34/70 [48%]; p<0·0001), and early diagnosis (median age 5·0 days, IQR 1·0-14·5 vs 45·5 days, IQR 27·2-95·0; p<0·0001). Remission of neonatal diabetes mellitus occurred in 89 (51%) index patients at a median age of 17 weeks (IQR 9·5-39·0; median follow-up 4·7 years, IQR 1·5-12·8). Recurrence was common, with no difference between the groups who had 6q24 abnormalities versus mutations in KATP channel subunit genes (82% vs 86%; p=0·36).
INTERPRETATION: Neonatal diabetes mellitus is often associated with neuropsychological dysfunction and developmental defects that are specific to the underlying genetic abnormality. A multidisciplinary assessment is therefore essential when patients are diagnosed. Features of neuropsychological dysfunction and developmental defects should be tested for in adults with a history of neonatal diabetes mellitus. FUNDING: Agence Nationale de la Recherche-Maladies Rares Research Program Grant, the Transnational European Research Grant on Rare Diseases, the Société Francophone du Diabète-Association Française du Diabète, the Association Française du Diabète, Aide aux Jeunes Diabétiques, a CIFRE grant from the French Government, HRA-Pharma, the French Ministry of Education and Research, and the Société Française de Pédiatrie.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24622368     DOI: 10.1016/S2213-8587(13)70059-7

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  29 in total

Review 1.  ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target.

Authors:  Peter T Nelson; Gregory A Jicha; Wang-Xia Wang; Eseosa Ighodaro; Sergey Artiushin; Colin G Nichols; David W Fardo
Journal:  Ageing Res Rev       Date:  2015-07-28       Impact factor: 10.895

2.  Precision medicine in KCNJ11 permanent neonatal diabetes.

Authors:  Siri Atma W Greeley; Lisa R Letourneau; Louis H Philipson
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-04       Impact factor: 32.069

3.  Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures.

Authors:  Monica S Lanning; David Carmody; Łukasz Szczerbiński; Lisa R Letourneau; Rochelle N Naylor; Siri Atma W Greeley
Journal:  Pediatr Diabetes       Date:  2017-12-05       Impact factor: 4.866

Review 4.  Monogenic diabetes: the impact of making the right diagnosis.

Authors:  Anastasia G Harris; Lisa R Letourneau; Siri Atma W Greeley
Journal:  Curr Opin Pediatr       Date:  2018-08       Impact factor: 2.856

5.  Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.

Authors:  David Carmody; Charles D Bell; Jessica L Hwang; Jazzmyne T Dickens; Daniela I Sima; Dania L Felipe; Carrie A Zimmer; Ajuah O Davis; Kateryna Kotlyarevska; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

6.  ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes.

Authors:  Karen A Landmeier; Monica Lanning; David Carmody; Siri Atma W Greeley; Michael E Msall
Journal:  Pediatr Diabetes       Date:  2016-08-24       Impact factor: 4.866

Review 7.  Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations.

Authors:  Lisa R Letourneau; Siri Atma W Greeley
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

8.  Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.

Authors:  Naïm Bouazza; Zoubir Djerada; Claire Gozalo; Kanetee Busiah; Jacques Beltrand; Marianne Berdugo; Saik Urien; Jean-Marc Treluyer; Michel Polak
Journal:  Eur J Clin Pharmacol       Date:  2016-08-25       Impact factor: 2.953

9.  Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls.

Authors:  D Carmody; A N Pastore; K A Landmeier; L R Letourneau; R Martin; J L Hwang; R N Naylor; S J Hunter; M E Msall; L H Philipson; M N Scott; S A W Greeley
Journal:  Diabet Med       Date:  2016-06-22       Impact factor: 4.359

10.  Cognitive, Neurological, and Behavioral Features in Adults With KCNJ11 Neonatal Diabetes.

Authors:  Pamela Bowman; Jacob Day; Lorna Torrens; Maggie H Shepherd; Bridget A Knight; Tamsin J Ford; Sarah E Flanagan; Ali Chakera; Andrew T Hattersley; Adam Zeman
Journal:  Diabetes Care       Date:  2018-10-30       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.